On October 17, Hims & Hers Health Inc. fell 5.07% in Regular Trading, trading at $27.87 per share, with turnover of $216 million.
The move coincided with continued market focus on the company’s Australia expansion after it launched the Hers women’s health platform there, rebranding the existing Juniper service and broadening offerings into hair regrowth, menopause and perimenopause, and weight management following its earlier acquisition of Eucalyptus.
That rollout has also revived investor attention on profitability pressure previously flagged by management. In its August quarterly updates and conference call, the company said international expansion and weight-management business growth would keep gross margin below historical levels, while the CFO said international operations and weight-loss products weighed on second-quarter margins. Those comments help explain why the Australia launch, while strategically important, may be viewed as incrementally costly in the near term.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments